NCT01488838

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: King Faisal Specialist Hospital & Research Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Randomized Phase II study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation alone in Resected High-Risk Malignant Salivary Gland Tumors

Conditions

• Malignant Salivary Gland Tumors

Interventions

Type	Name	Description
DRUG	Cisplatin: 40 mg/m2 weekly during radiation	Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
RADIATION	Radiation: 60-66 Gy in 2 Gy daily fractions	Radiation: 60-66 Gy in 2 Gy daily fractions

Timeline

• Start date: 2011-11-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2011-12-08
• Last updated: 2016-02-25

Locations

1 site across 1 country: Saudi Arabia